Exelixis Shares Rising on CABOMETYX Revenue

Exelixis reported Q2 2026 revenue of $629 million, including $573 million from CABOMETYX, up 10% year over year, and GAAP net income of $212 million, or $0.82 per diluted share. The company ended the quarter with $1.4 billion in cash and repurchased $312 million of stock, while EXEL shares were up 34% year to date. The bullish commentary cites institutional buying activity, 13% three-year sales growth, 83.6% three-year EPS growth, and estimates for EPS to rise 17.7% this year.

Analysis

EXEL’s investable distinction versus most oncology peers is the conversion of a mature commercial franchise into earnings and capital returns rather than binary pipeline optionality. The key vulnerability is concentration: CABOMETYX represents roughly 91% of reported revenue, so incremental share loss in renal-cell carcinoma or a change in combination-treatment standards has an outsized effect on both revenue growth and the multiple. Merck’s KEYTRUDA-based regimens, BMS’s OPDIVO/YERVOY franchise, Eisai/Merck’s LENVIMA combinations, and Peloton/Merck’s WELIREG are the clinically relevant competitive watchlist—not generic biotech sentiment.

Near term, the buyback can support the stock during healthcare-factor weakness, but it should not be extrapolated as a recurring annual capital-return rate without free-cash-flow and authorization data. The promotional emphasis on unusual volume is not an independently investable catalyst; after a strong YTD move, positioning can amplify a downside reaction if guidance merely holds rather than rises. The next 1-3 month catalyst path is prescription/share trends and management’s view of growth durability; the 6-18 month question is whether pipeline assets or label expansion diversify the revenue base before CABOMETYX faces more meaningful competitive erosion.

Consensus appears to be rewarding quality earnings while underweighting the franchise-concentration discount. That discount is justified if CABOMETYX growth decelerates into low single digits, but could close if EXEL demonstrates durable share gains or produces credible late-stage pipeline validation. A guidance raise tied to demand—not inventory, pricing, or one-time milestone revenue—would falsify the cautious view; conversely, any downward revision to product-growth expectations should be treated as a multiple-compression event rather than a modest earnings miss.

Key Decisions for Investors

• Do not chase EXEL solely on reported institutional-flow signals. Establish a watch entry after the next earnings call only if management raises full-year product-revenue guidance and provides evidence of sustained prescription/share momentum; target a 6-12 month holding period.
• For existing EXEL longs, retain but reduce exposure if CABOMETYX growth guidance falls to low single digits or if competitive commentary suggests loss of first-line renal-cell carcinoma share. The revenue concentration means a 10% product-sales shortfall would likely drive a materially larger EPS and valuation reaction than for diversified large-cap pharma.
• Consider a 3-6 month quality-biotech pair: long EXEL versus short XBI, sized beta-neutral, only if EXEL’s post-results relative strength holds. The thesis is profitable, self-funded oncology exposure versus the index’s higher binary-trial and financing sensitivity; exit if EXEL underperforms XBI by 10% after the next catalyst.
• Avoid a directional options recommendation until implied volatility, strike skew, and upcoming clinical/regulatory dates are available. If implied volatility is below its one-year percentile ahead of a material pipeline readout, revisit defined-risk call spreads rather than owning unhedged downside in a single-product equity.